AstraZeneca PLC (AZN)

AZN Balance Sheet

Assets, liabilities, and equity analysis

AZN Quarterly Balance Sheet (USD)

Quarterly Report	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/30/2025	12/31/2024	09/30/2024	06/30/2024
Total Current Assets	29.613B	29.613B	28.723B	29.940B	28.939B	26.139B	25.827B	24.155B	25.393B
Cash & Cash Equivalents	7.560B	7.560B	5.711B	8.143B	7.058B	5.230B	5.488B	4.797B	6.916B
Short-Term Investments	115.000M	115.000M	30.000M	39.000M	50.000M	165.000M	166.000M	133.000M	160.000M
Cash & Short-Term Investments	7.675B	7.675B	5.741B	8.182B	7.108B	5.395B	5.654B	4.930B	7.076B
Accounts Receivable	14.106B	14.106B	15.177B	14.338B	14.168B	13.250B	12.972B	11.879B	11.047B
Inventory	6.570B	6.570B	6.557B	6.593B	6.467B	5.884B	5.288B	5.662B	5.667B
Total Assets	114.015B	114.015B	114.074B	114.456B	112.422B	106.253B	104.035B	104.922B	104.340B
Property, Plant & Equipment	14.941B	14.941B	14.703B	13.783B	13.229B	12.303B	11.647B	11.513B	10.833B
Goodwill	21.194B	21.194B	21.242B	21.219B	21.222B	21.130B	21.025B	21.139B	21.060B
Intangible Assets	36.908B	36.908B	37.846B	38.191B	37.925B	37.550B	37.177B	39.394B	39.426B
Long-Term Investments	4.244B	4.244B	2.525B	2.286B	4.851B	1.900B	1.734B	2.012B	0.00
Total Current Liabilities	32.570B	32.570B	30.617B	34.054B	33.536B	29.129B	27.866B	25.926B	28.566B
Accounts Payable	22.505B	22.505B	25.280B	25.028B	23.986B	22.544B	22.465B	21.684B	20.463B
Short-Term Debt	7.576B	7.576B	3.185B	6.203B	6.492B	3.425B	2.156B	1.253B	5.067B
Total Liabilities	66.631B	66.631B	65.355B	68.485B	67.612B	65.122B	63.164B	64.117B	64.742B
Long-Term Debt	24.454B	24.454B	24.715B	24.700B	24.714B	26.741B	26.506B	28.887B	27.225B
Total Debt	33.918B	33.918B	29.703B	32.661B	32.839B	31.717B	30.114B	31.562B	33.533B
Net Debt (Cash)	26.358B	26.358B	23.992B	24.518B	25.781B	26.487B	24.626B	26.765B	26.617B
Total Shareholders' Equity	47.333B	47.333B	48.667B	45.888B	44.719B	41.039B	40.786B	40.719B	39.512B
Common Stock	388.000M	388.000M	388.000M	388.000M	388.000M	388.000M	388.000M	388.000M	388.000M
Retained Earnings	9.672B	9.672B	10.972B	8.213B	7.023B	3.364B	3.160B	3.138B	1.847B
Current Ratio	0.91	0.91	0.94	0.88	0.86	0.90	0.93	0.93	0.89
Debt to Equity Ratio	0.72	0.72	0.61	0.71	0.73	0.77	0.74	0.78	0.85

AZN Annual Balance Sheet (USD)

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Total Current Assets	28.723B	25.827B	25.054B	22.593B	26.244B	19.544B	15.563B	15.591B
Cash & Cash Equivalents	5.711B	5.488B	5.840B	6.166B	6.329B	7.832B	5.368B	4.831B
Short-Term Investments	30.000M	37.000M	20.000M	77.000M	69.000M	160.000M	849.000M	849.000M
Cash & Short-Term Investments	5.741B	5.525B	5.860B	6.243B	6.398B	7.992B	6.217B	5.680B
Accounts Receivable	15.177B	11.235B	8.407B	9.192B	8.132B	5.651B	4.896B	2.995B
Inventory	6.557B	5.288B	5.424B	4.699B	8.983B	4.024B	3.193B	2.890B
Total Assets	114.074B	104.035B	101.119B	96.483B	105.363B	66.729B	61.377B	60.651B
Property, Plant & Equipment	14.703B	11.647B	10.502B	9.449B	10.171B	8.917B	8.335B	7.421B
Goodwill	21.242B	21.025B	20.048B	19.820B	19.997B	11.845B	11.668B	11.707B
Intangible Assets	37.846B	37.177B	38.089B	39.307B	42.387B	20.947B	20.833B	21.959B
Long-Term Investments	2.525B	0.00	1.777B	0.00	0.00	0.00	0.00	113.000M
Total Current Liabilities	30.617B	27.866B	30.542B	26.293B	22.594B	20.307B	18.117B	16.292B
Accounts Payable	25.280B	3.640B	3.267B	2.550B	2.824B	2.350B	1.774B	1.720B
Short-Term Debt	3.185B	2.156B	5.129B	5.225B	1.567B	2.194B	1.822B	1.781B
Total Liabilities	65.355B	63.164B	61.953B	59.425B	66.076B	51.091B	46.781B	46.607B
Long-Term Debt	24.715B	26.506B	22.365B	22.965B	28.134B	17.505B	15.730B	19.201B
Total Debt	29.703B	30.114B	28.622B	29.143B	30.688B	20.380B	18.227B	19.113B
Net Debt (Cash)	23.992B	24.626B	22.782B	22.977B	24.359B	12.548B	12.859B	14.282B
Total Shareholders' Equity	48.667B	40.786B	39.143B	37.037B	39.268B	15.622B	13.127B	12.468B
Common Stock	388.000M	388.000M	388.000M	387.000M	387.000M	328.000M	328.000M	317.000M
Retained Earnings	10.972B	3.160B	4.516B	-574.000M	1.710B	5.299B	2.812B	5.683B
Current Ratio	0.94	0.93	0.82	0.86	1.16	0.96	0.86	0.96
Debt to Equity Ratio	0.61	0.74	0.73	0.79	0.78	1.30	1.39	1.53

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About AstraZeneca PLC

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

Cambridge

94,300 employees

www.astrazeneca.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Pascal Claude Roland Soriot

View full financials